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Summary
The levels of the neuropeptides Met- and Leu-enkephalin
(MET-ENK, LEU-ENK), substance P and neurotensin were
measured by a combined high performance liquid chromato-
graphy/radioimmunoassay (HPLC/RIA) method in post-
mortem samples of basal ganglia from Parkinson's disease
patients, incidental Lewy body disease patients (pre-
symptomatic Parkinson's disease) and matched controls.
Dopamine (DA) levels were reduced in the caudate nucleus
and putamen in Parkinson's disease, but unaltered in inci-
dental Lewv body disease. The levels of MET-ENK were
reduced in the caudate nucleus, putamen and substantia
nigra in Parkinson's disease. Met-enkephalin levels were
reduced in the caudate nucleus and in the putamen in
incidental Lewy body disease. Leu-enkephalin levels were
decreased in the putamen and were undetectable in the
substantia nigra in Parkinson's disease. Leu-enkephalin levels
were unchanged in incidental Lewy body disease, although
there was a tendency to a reduction in putamen. Substance
P levels were reduced in the putamen in Parkinson's disease.
No significant changes in substance P content were observed
in incidental Lewy body disease. Neurotensin levels were
increased in the substantia nigra in Parkinson's disease.
Neurotensin levels in incidental Lewy body disease were not
altered significantly, but tended to parallel the changes in
Parkinson's disease. The changes in basal ganglia peptide
levels in incidental Lewy body disease generally followed a
trend similar to those seen in Parkinson's disease, but were
less marked. This suggests that they are an integral part of
the pathology of the illness and not secondary to DA neuronal
loss or a consequence of prolonged drug therapy.
Keywords: Parkinson's disease; incidental Lewy body disease; basal ganglia; neuropeptides; high performance liquid
chromatography
Abbreviations: DA = dopamine; HPLC = high performance liquid chromatography; L-dopa = L-3,4-dihydroxyphenylalanine;
LEU-ENK = Leu-enkephalin; MET-ENK = Met-enkephalin; MPTP = l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine; 6-
OHDA = 6-hydroxydopamine; RIA = radioimmunoanalysis
Introduction
The destruction of the nigrostriatal pathway with the presence
of Lewy bodies in remaining nigral neurons underlies the
motor deficit which characterizes Parkinson's disease (Gibb,
1987; Gibb and Lees, 1988). A marked reduction in striatal
DA is the main biochemical deficit occurring in Parkinson's
disease. Replacement therapy with L-3,4-dihydroxyphenylal-
anine (L-dopa) initially reverses the motor symptoms. How-
ever, with continued treatment the therapeutic response
diminishes and motor complications (fluctuations and dys-
kinesias) usually appear. The involvement of neurotransmitter
systems other than DA may contribute to the symptomatology
© Oxford University Press 1996
of Parkinson's disease. In particular, a highly regional pattern
of changes in neuropeptide levels in basal ganglia occurs in
Parkinson's disease (Agid and Javoy-Agid, 1985).
In studies of post-mortem brain material in Parkinson's
disease, MET-ENK and LEU-ENK levels have been reported
to be reduced in the caudate nucleus and putamen, and there
is also a reduction of MET-ENK content in substantia nigra
(Taquet et al., 1983; Llorens-Cortes et al., 1984; Fernandez
et al., 1992). Substance P levels have been reported to be
decreased in the caudate nucleus, globus pallidus and
substantia nigra (Mauborgne et al., 1983; Fernandez et al.,
 at CSIC on D
ecem
ber 13, 2012
http://brain.oxfordjournals.org/
D
ow
nloaded from
 
824 A. Fernandez et al.
1992). In contrast, neurotensin levels have been reported as
either unaltered throughout basal ganglia (Bissette et al.,
1985; Emson et al., 1985) or increased in substantia nigra
(Fernandez et al., 1995). Immunocytochemical studies show
a different pattern of change with substance P and MET-
ENK immunostaining either unaltered (Grafe et al., 1985;
Waters et al., 1988) or even increased in striatum and globus
pallidus (Grafe et al., 1985; Goto et al., 1990) and unchanged
in the substantia nigra (Waters et al., 1988).
It is not known whether these peptide changes are part of
the primary pathology of Parkinson's disease, whether they
occur secondary to the loss of DA neurons, or whether they
are a result of prolonged drug therapy with L-dopa. We have
examined these questions by utilizing animal models of
Parkinson's disease such as the unilateral 6-hydroxydopamine
(6-OHDA) lesioned rat (Taylor et al., 1992), in combination
with L-dopa treatment for 6 months, or the l-methyl-4-
phenyl-l,2,3,6-tetrahydropyridine (MPTP) treated parkin-
sonian primate (Jenner et al., 1986; Taquet et al., 1988;
Taylor et al., 1991). Overall, the effects of nigrostriatal
degeneration on basal ganglia peptide levels did not parallel
the alterations in peptide content observed in Parkinson's
disease. This suggested that they may be part of the primary
pathological process occurring in Parkinson's disease.
To confirm this conclusion using post-mortem tissue from
patients with Parkinson's disease is difficult. Brain material
from early or untreated parkinsonians is not available.
Consequently, we have investigated peptide content in basal
ganglia in Parkinson's disease and in brain material from the
8-10% of normal individuals who at, post-mortem, are found
to have evidence for nigral cell death and Lewy bodies
(incidental Lewy body disease). Incidental Lewy body disease
is considered to be the presymptomatic phase of Parkinson's
disease (Forno and Alvord, 1971; Fearnley and Lees, 1991),
since the distribution of pigmented cell loss observed in
incidental Lewy body disease, although less severe, mirrors
that of Parkinson's disease (Gibb, 1987; Fearnley and Lees,
1991).
Patients and methods
Patients
Brain tissue was obtained from the Parkinson's Disease
Society Brain Bank (London, UK) and from the Depart-
ment of Pathology (University of Innsbruck, Austria). The
dissection of all brain material was undertaken by Dr F. R.
Wells at the Parkinson's Disease Society Brain Bank. The
brains were divided midsagittally with one-half immersion
fixed in 10% buffered formalin and the other frozen at -70°C.
The brain tissue was dissected from frozen brain and stored
at-70°C until biochemical analysis (Dexter et al., 1989).
Controls consisted of five males and one female (mean
age±SE, 68.3±5.7 years), who died without any neurological
or psychiatric disease. Pathological examination of the brains
did not show cell loss or Lewy bodies in haematoxylin-eosin
stained sections of substantia nigra. Fifty control brains were
screened to detect cases of incidental Lewy body disease.
Incidental Lewy body disease was diagnosed in six apparently
normal individuals (three males and three females; mean
age±SE, 68.2±5.8 years) whose brains exhibited cell loss
in the substantia nigra and the presence of Lewy bodies in
remaining neurons at post-mortem examination. Other basal
ganglia regions showed no overt pathological changes.
However, other nuclei such as the locus coeruleus and nucleus
basalis of Meynert were also involved, indicating that the
regional distribution of the lesions was identical to that in
Parkinson's disease. These brains were pathologically defined
and validated as incidental Lewy body disease cases (Gibb
and Lees, 1988; Fearnley and Lees, 1991). Patients found
to have incidental Lewy body disease were not known to
have neurological symptoms or signs in life and had not
received drug treatment. Parkinson's disease patients
consisted of four males and two females (mean age±SE,
78.7±2.1 years), who were clinically diagnosed and histo-
pathologically defined by the presence of Lewy bodies and
a characteristic pattern of neuronal loss in the substantia
nigra. The age of onset of Parkinson's disease ranged between
59 and 73 years (mean±SE, 69.2±3.1 years) and the duration
of the disease ranged from 5 to 14 years (mean±SE,
10.4±1.6 years). All the Parkinson's disease patients were
receiving L-dopa (with a peripheral dopa decarboxylase
inhibitor) at the time of death. The doses ranged between
200 and 1000 mg kg day-' (mean±SE, 550±154 mg kg
day"1)- The average time between death and refrigeration of
the body did not differ between the three groups of subjects
(mean±SE, controls 2.9±0.2 h; incidental Lewy body disease
2.7±0.3 h and Parkinson's disease 2.8±0.4 h), and the
average times between death and brain removal were similar
(mean±SE, controls 14.3±1.5 h; incidental Lewy body
disease 21.5±2.2 h and Parkinson's disease 16.6±1.7 h).
Determination of levels of dopamine and its
metabolites
The levels of DA and its metabolites in samples from the
caudate nucleus and putamen were measured by a standard
HPLC technique with electrochemical detection (Wagner
et al., 1982).
Peptide measurements
For peptide measurements, frozen samples were weighed
and boiled for 15 min in 100 volumes of a mixture of 1 N
acetic acid and 0.02 N HC1 containing 2-mercaptoethanol.
Samples were homogenized with an Ultraturrax homogenizer
(20 000 r.p.m., 6 s) and centrifuged at 12 000 g for 10 min
at 4°C. After centrifugation, aliquots of the supernatant were
freeze-dried and stored at -20°C until assayed.
Met-enkephalin, LEU-ENK and neurotensin were
measured by radioimmunoanalysis (RIA), following HPLC
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Table 1 Levels of dopamine, dihydroxyphenylacetic acid, homovanillic acid and dopamine turnover ratio in the caudate
nucleus and putamen from normal subjects, incidental Lewy body disease patients and Parkinson's disease patients
Caudate
Control
+Lb
Parkinson's disease
Putamen
Control
+Lb
Parkinson's disease
DA
3.09±0.56
3.08±0.82
0.42±0.23"
3.36±0.42
3.33±0.47
0.16±0.06*"
DOPAC
0.26±0.07
0.25 ±0.15
0.11 ±0.04
0.38±0.13
0.25±0.11
0.06±0.01*
HVA
3.48±0.57
3.51 ±0.32
2.50+0.53
8.27±0.87
6.86+1.10
1.85±0.38"
HVA + DOPAC/DA
1.37±0.24
1.89±0.66
16.04±5.99*"
2.82±0.48
2.29±0.35
23.77±3.53*"
Results are given as mean±SE expressed as micrograms per gram wet weight of tissue (n = 6). DOPAC = dihydroxyphenylacetic acid;
HVA = homovanillic acid; +Lb = Lewy body disease patients. *P < 0.05; **P < 0.01; ***P < 0.001: compared with control subjects
(ANOVA, Student's / test).
SN
Fig. 1 Met-enkephalin levels in control subjects (C-Lb),
incidental Lewy body (C+Lb) and Parkinson's disease (PD)
patients in basal ganglia regions. CN = caudate nucleus;
Put = putamen; GPL = globus pallidus lateral segment;
GPM = globus pallidus medial segment; SN = substantia nigra.
The results are means ±SE (n = 6). *P < 0.05 (ANOVA,
Student's t test).
separation of the crude extracts, as previously described
(de Ceballos et al., 1991). Substance P was quantified in the
crude extracts and levels correspond to immunoreactive-like
material. The identity of the substance P immunoreactivity
detected by RIA was established by HPLC separation of the
extracts and shown to correspond to both authentic and
oxidized peptide.
All the antisera used in the RIA were raised at the Cajal
Institute with the exception of MET-ENK antiserum which
was purchased from Amersham International (Amersham,
UK). The antisera did not display any cross-reactivity with
related or unrelated peptides, with the exception of substance
P antiserum which cross-reacted 50% with oxidized substance
P, MET-ENK antisera which cross-reacted 10% with oxidized
MET-ENK, 6% with LEU-ENK and 2% with MET-ENK-
Arg-Phe, and LEU-ENK antisera which cross-reacted 3%
with MET-ENK. Aliquots of' 25I-peptides (100 u.1; 7000 c.p.m.;
Amersham International, UK) were incubated with 100 u.1 of
standards or samples and 100 |il of antiserum in a final volume
of 600 \x\ of RIA buffer (50 mM sodium phosphate buffer,
Fig. 2 Leu-enkephalin levels in control subjects (C-Lb), incidental
Lewy body (C+Lb) and Parkinson's disease (PD) patients in
basal ganglia regions. CN = caudate nucleus; Put = putamen;
GPL = globus pallidus lateral segment; GPM globus pallidus
medial segment; SN = substantia nigra. The results are
means±SE (n = 6). *P < 0.05 (ANOVA, Student's t test).
pH 7.4, containing either 0.2% gelatin for enkephalins or
0.3% bovine serum albumin for substance P and neurotensin).
After 16-20 h incubation at 4°C, bound and free peptide was
separated using activated charcoal.
Serial dilutions of the crude extracts or HPLC purified
samples gave competition curves parallel to those obtained
with the synthetic peptides. From these experiments, the
appropiate dilution for each area and group of patients was
selected. Sensitivity of the RIA (15% of bound tracer) was
2 fmol for each peptide.
Statistical analysis
Analysis of differences between groups was performed using
one-factor ANOVA followed by unpaired Student's t test.
Correlations between individual biochemical levels with
different ante- and post-mortem parameters were sought
using Pearson's coefficient.
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CN SN
Fig. 3 Substance P levels in control subjects (C-Lb), incidental
Lewy body (C + Lb) and Parkinson's disease (PD) patients in
basal ganglia regions. CN = caudate nucleus; Put = putamen;
GPL = globus pallidus lateral segment; GPM = globus pallidus
medial segment; SN = substantia nigra. The results are
means±SE (n = 6). *P < 0.05 (ANOVA, Student's / test).
Fig. 4 Neurotensin levels in control subjects (C-Lb), incidental
Lewy body (C + Lb) and Parkinson's disease (PD) patients in
basal ganglia regions. GPL = globus pallidus lateral segment;
GPM = globus pallidus medial segment; SN = substantia nigra.
The results are means±SE (n = 6). *P < 0.05 (ANOVA,
Student's ; test).
Results
Dopamine levels in Parkison's disease and
incidental Lewy body disease
Dopamine levels were significantly reduced in the caudate
nucleus (by 87%) and putamen (by 95%) in patients with
Parkinson's disease compared with controls (Table 1). Levels
of homovanillic acid and dihydroxyphenylacetic acid were
unaltered in the caudate nucleus, but were reduced in the
putamen in Parkinson's disease. Dopamine turnover measured
by the ratio of (homovanillic acid+dihydroxyphenylacetic
acid):DA was enhanced in both caudate and putamen in
Parkinson's disease. In individuals with incidental Lewy body
disease, there was no change in the caudate or putamen DA
content or in DA metabolite levels or DA turnover (Table 1).
Basal ganglia neuropeptide alterations in
Parkinson's disease and incidental Lewy body
disease
There was a parallel reduction (-50%) in MET-ENK levels
in the caudate nucleus in Parkinson's disease and in
incidental Lewy body disease compared with controls
(Fig. 1). There was a reduction in MET-ENK levels in
putamen (90% decrease versus controls) and in substantia
nigra (60% decrease versus controls) in Parkinson's disease.
Met-enkephalin levels were also reduced by over 50% in the
putamen (but not in substantia nigra) in incidental Lewy
body cases. Met-enkephalin concentrations were increased
in both segments of the globus pallidus in Parkinson's disease
but the changes were not statistically significant. A similar
increase was found in incidental Lewy body disease patients,
but again the differences did not reach statistical significance.
Leu-enkephalin levels in the caudate nucleus and both
segments of globus pallidus were unaltered in Parkinson's
disease and in incidental Lewy body disease compared with
controls (Fig. 2). In contrast, LEU-ENK concentrations were
markedly reduced in the putamen and were undetectable in
the substantia nigra in Parkinson's disease. There was a
reduction of LEU-ENK content in the putamen in incidental
Lewy body disease, but this was not statistical significant.
There was a decrease in substance P concentrations in the
putamen in Parkinson's disease (Fig. 3). Substance P content
was non-significantly increased in the lateral and medial
globus pallidus in both Parkinson's disease and incidental
Lewy body disease (Fig. 3). Substance P levels in the
caudate nucleus and substantia nigra were unaltered in
either Parkinson's disease or incidental Lewy body disease
compared with controls.
The small amount of tissue available and the low levels
of neurotensin in striatal areas precluded the analysis of this
peptide in the caudate nucleus and putamen. Neurotensin
levels were increased (two-fold) in the substantia nigra of
Parkinson's disease patients (Fig. 4). Neurotensin concentra-
tions in the incidental Lewy body disease group followed
the same trends to those seen in Parkinson's disease but the
changes did not reach statistical significance.
Correlations of peptide levels and with ante- or
post-mortem parameters
There was no correlation of individual peptide levels with
either sex, age. time to refrigeration or to autopsy (data not
shown). There were significant positive correlations between
MET-ENK and LEU-ENK levels in the caudate nucleus,
putamen and globus pallidus. For example, in the putamen
both peptides were correlated in control subjects (0.903), in
incidental Lewy disease cases (0.856) and in Parkinson's
disease patients (0.904). Individual MET-ENK and substance
P levels in medial globus pallidus were correlated in incidental
Lewy disease patients and Parkinson's disease patients. In
agreement with previous studies, DA content in caudate
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Table 2 Summary of alterations in peptide levels in Parkinson's disease and in unilateral 6-OHDA lesioned rats (untreated
or treated with L-dopa)
Peptide Brain area Parkinson's disease
I(+Lb)
I/T
i
i
i/=
=/i
i
ini/=
=
6-0
T
T
=
ND
i
i/=
ND
i
T
T
6-OHDA + L-dopa
MET-ENK
LEU-ENK
SP
NT
Striatum
Globus pallidus
Substantia nigra
Striatum
Globus pallidus
Substantia nigra
Striatum
Globus pallidus
Substantia nigra
Striatum
Globus pallidus
Substantia nigra =/T
TT
TT
t
T
ND
TT
T
ND
T
ND
T
Parkinson's disease alterations in peptide content in previous studies and in this study. Data from lesioned rats (6-OHDA-lesioned rats
untreated or treated with L-dopa) are from Engber et al. (1991) and Taylor el al. (1992). 6-OHDA = 6-hydroxydopamine;
L-dopa = L-3,4-dihydroxyphenylalanine; striatum = caudate nucleus and/or putamen; SP = substance P; NT = neurotensin.
-I = decreased; T = increased; = = unchanged, compared with controls; ND = not determined. Striatal MET-ENK levels were also
reduced in incidental Lewy body disease (+Lb).
nucleus in Parkinson's disease was positively correlated with
the age of onset of the illness (0.8644), but was negatively
correlated with the duration of the disease (-0.8357). There
was no correlation between individual peptide levels in any
region and L-dopa dose.
Discussion
The relative distribution of neuropeptide levels in control
subjects was in general agreement with those previously
reported (Buck et al., 1981; Cooper et al., 1981; Manberg
et al., 1982; Mauborgne et al., 1983; Taquet et al., 1983;
Llorens-Cortes et al., 1984). However, in this work the ratio
of enkephalin content in globus pallidus lateral segment to
either caudate nucleus or putamen was not in accordance
with previous studies (e.g. Taquet et al., 1983; Llorens-
Cortes et al., 1984). This a consequence of the HPLC/
RIA technique used for the peptide measurements. As we
previously reported (de Ceballos et al., 1991), there is a
disparity between apparent peptide levels in crude extracts
with those of authentic peptides as determined after HPLC
purification. Indeed, in recent studies using another series of
controls and Parkinson's disease brains, we have shown that
MET-ENK levels in globus pallidus lateral segment are
double those in caudate nucleus or putamen when measured
in crude extracts, but are very similar in HPLC purified
controls (de Ceballos et al., unpublished observations).
Some neuropeptide alterations occurring in the brains of
those with established Parkinson's disease on L-dopa treatment
are also present in incidental Lewy body disease. Since these
individuals were normal in life and did not receive L-dopa
therapy, and since the extent of pathological change in the
substantia nigra was small and was not associated with any
change in caudate or putamen DA content, such alterations
in neuropeptide levels may reflect part of the primary
pathology of Parkinson's disease.
In agreement with previous studies MET-ENK content was
decreased in the caudate nucleus (Fernandez et al., 1992;
Sivam, 1991), putamen and substantia nigra in Parkinson's
disease (Taquet et al., 1983; Llorens-Cortes et al., 1984).
In incidental Lewy body disease a significant reduction in
MET-ENK levels was also observed in the caudate nucleus
and the putamen. In 6-OHDA lesioned rats or in MPTP
treated monkeys, there were increased striatal MET-ENK
levels (Thai et al., 1983; Sivam et al., 1987; Dacko and
Schneider, 1991; Taylor et al.. 1991, 1992). Therefore, the
decrease observed in Parkinson's disease and in incidental
Lewy body disease does not appear to be a consequence
of nigrostriatal pathway degeneration. In contrast, in both
segments of the globus pallidus, MET-ENK content tended
to be increased in both Parkinson's disease (Grafe et al.,
1985; Goto et al., 1990; de Ceballos et al.. 1993) and
incidental Lewy body disease. This change is similar to that
seen in 6-OHDA and MPTP lesioned animals (Thai et al.,
1983; Sivam et al., 1987; Taylor et al., 1991), so may be a
reflection of nigrostriatal loss. The changes observed in
incidental Lewy body disease cannot be ascribed to L-dopa
therapy, but may reflect the underlying disease process
(Table 2).
In 6-OHDA lesioned rodents and in MPTP treated primates,
the lesion induced increase in MET-ENK levels is a
consequence of increased preproenkephalin gene expression
(Angulo et al., 1986; Young et al., 1986; Sivam et al., 1987;
Augood et al., 1989; Gerfen et al., 1990). It has been recently
reported that preproenkephalin gene expression is enhanced
in parkinsonian caudate nucleus and putamen (Nisbet et al.,
1995). Although this might explain the tendency to an
increase in MET-ENK levels in globus pallidus, the main
projection area of the striopallidal enkephalin pathway, is
difficult to reconcile with the observation of a decrease in
striatal levels of MET-ENK in Parkinson's disease. However.
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increased biosynthesis accompanied by decreased levels may
be a result of increased release of MET-ENK.
Changes in LEU-ENK levels partly paralleled those of
MET-ENK. Thus, LEU-ENK levels were reduced in putamen
(Taquet et al., 1983) and substantia nigra of patients with
Parkinson's disease. The marked correlation between the
levels of MET-ENK and LEU-ENK strongly suggests that
both peptides derive from the same precursor, pre-
proenkephalin (Gublerefa/., 1982). There was no statistically
significant changes in LEU-ENK levels in incidental Lewy
body disease, although those in putamen were considerably
reduced. Changes in LEU-ENK levels appear to be
characteristic of Parkinson's disease since a nigrostriatal
lesion does not alter striatal LEU-ENK levels (Jenner et al.,
1986; Taylor et al., 1991, 1992). Furthermore, although there
is a lesion-induced decrease in LEU-ENK levels in substantia
nigra, this was reversed by L-dopa, such that it increased
seven-fold compared with values for control rats (Taylor
et al., 1992).
In the present study, substance P levels were decreased
in the putamen (Mauborgne et al., 1983), tended to increase
in globus pallidus (Grafe et al., 1985; Goto et al., 1990;
de Ceballos et al., 1993) and were unchanged in substantia
nigra (Grafe et al., 1985; Waters et al., 1988) in Parkinson's
disease in agreement with some previous findings. In 6-
OHDA lesioned rats, decreased striatal (Lindefors et al.,
1989) and nigral substance P content and decreased
preprotachykinin mRNA has been reported (Young et al.,
1986; Sivam et al., 1987; Gerfen et al., 1990; Engber et al.,
1991; Taylor et al., 1992). L-Dopa treatment completely
reversed the reduction in substance P content in substantia
nigra in such animals (Engber et al., 1991; Taylor et al.,
1992) (Table 2). Thus, the absence of change in nigral
substance P levels in Parkinson's disease (Grafe et al., 1985;
Waters et al., 1988) may be viewed as a combined effect
of nigostriatal pathway degeneration and L-dopa treatment.
Indeed, pre-protachykinin mRNA levels are also unaltered
in Parkinson's disease patients treated with L-dopa (Nisbet
et al., 1995).
Neurotensin content in substantia nigra was increased in
Parkinson's disease (Fernandez et al., 1995), and no
statistically significant changes were observed in globus
pallidus. In another series of Parkinson's disease patients,
neurotensin levels were shown to be increased in both
zona compacta and zona reticulata of the substantia nigra
(Fernandez et al., 1995). In incidental Lewy body disease,
neurotensin levels only tended to similar changes in these
structures. Following a nigrostriatal lesion there are increased
striatal and pallidal neurotensin levels, which are not modified
by L-dopa treatment. However, nigral neurotensin levels,
which were unchanged following a 6-OHDA lesion, were
increased by L-dopa treatment (Taylor et al., 1992). Thus,
changes in neurotensin levels appear to be secondary to DA
neuron loss in combination with prolonged drug therapy. The
fact that in incidental Lewy body disease patients only
tendencies were observed, further support this conclusion.
Hypokinetic disorders, such as Parkinson's disease, have
been postulated to result from the selective changes in the
different striofugal pathways (Albin et al., 1989), which
contain various neuropeptides as cotransmitters. Activity
in the pathway from striatum to lateral globus pallidus
(colocalizing enkephalins) is thought to be increased, while
activity in the pathway from striatum to medial globus
pallidus and substantia nigra (colocalizing tachykinins) is
thought to be decreased in Parkinson's disease. In this
study some of the observed alterations in peptide levels are
compatible with this scenario. However, the stationary levels
of a given peptide in a particular structure may not indicate
activity in a neuronal pathway. Thus, as argued above, the
reduced levels of MET-ENK and LEU-ENK in the striatum
in Parkinson's disease, especially in the putamen, and the
similar but less marked trends in incidental Lewy body
disease, may reflect increased release of the peptides due to
overactivity of such neurons containing enkephalins. This is
supported by the finding of increased proenkephalin mRNA
message in the striatum in Parkinson's disease (Nisbet et al.,
1995). With regard to substance P, the matter is more
complex, for L-dopa treatment reverses the decrease in pre-
protachykinin mRNA message in experimental animals with
lesions of the dopaminergic pathway {see above), and such
message is unchanged in Parkinson's disease striatum (Nisbet
et al., 1995). This might explain why substance P levels
were not significantly altered in medial globus pallidus and
especially in substantia nigra in Parkinson's disease.
The most important finding of the present study is that some
neuropeptide alterations occurring in Parkinson's disease
are also observed in incidental Lewy body disease. Most
convincing are the reductions in MET-ENK levels in striatum
in both disorders, which contrast with the increase found in
6-OHDA lesioned rats or MPTP treated monkeys. From these
results several conclusions can be drawn. First, such changes
in peptide levels may be characteristic of the disease and not
just secondary to DA neuron loss. Secondly, since similar
changes are observed in incidental Lewy body disease, they
may be an early component of the pathological process rather
than being secondary biochemical alterations resulting from
loss of the nigrostriatal pathway or a drug induced event.
Additional insight into the involvement of these basal ganglia
peptide systems in the pathophysiology of Parkinson's disease
could provide new therapeutic strategies for the illness.
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